



CryoLife SynerGraft Technology Highlighted At World Symposium On Heart Valve Disease

June 14, 1999

Business Editors/Health and Medical Writers

ATLANTA--(BW HealthWire)--June 14, 1999--

Paper Presented on Transpecies Heart Valve Transplants
Indicates Reduced Rejection Rates

CryoLife, Inc. (NYSE:CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, today announced that its SynerGraft(R) technology was featured in a presentation delivered yesterday, June 13, 1999, co-authored by Dr. Mark O'Brien, a paid consultant to CryoLife, Inc. and a member of the CryoLife Cardiovascular Medical Advisory Board. The paper, presented at the World Symposium on Heart Valve Disease in London, England, documents the use of CryoLife's SynerGraft technology in transplanting heart valves in laboratory animals. As detailed in the paper, porcine aortic valves which underwent the SynerGraft decellularization process and were implanted in sheep demonstrated minimal rejection as measured by inflammatory response.

Dr. Mark O'Brien said, "Based on the animal heart valve implants documented in this paper, I believe that the SynerGraft technology significantly reduces the potential for rejection of the donor organ by its host. In addition, the study indicates that not only is risk of rejection decreased, but there is also promise that host cells would repopulate the decellularized implant."

Steven G. Anderson, President and Chief Executive Officer of CryoLife, said, "This paper signals the potential importance our SynerGraft program can have in transpecies heart valve transplants without immunosuppression. We believe that our auto-xenograft technology reduces the risk of rejection and that SynerGraft regenerated tissue could become the basis for a new form of bioengineered heart valve which could be recellularized with host cells prior to implant."

Mr. Anderson added, "The goal of CryoLife's SynerGraft program is the development of a new biologic human heart valve. The program incorporates the use of a porcine heart valve which is depopulated of porcine cells, leaving a collagen matrix that is repopulated with human cells, providing a bioengineered human heart valve with similar structure and biodynamics as the patient's own heart valve."

The Company expects to file an Investigational Device Exemption (IDE) with the FDA in the fourth quarter of 1999 seeking approval to begin human clinical trials of its SynerGraft technology.

Founded in 1984, CryoLife, Inc. is the leader in the development and commercialization of implantable living human tissues for use in cardiovascular, vascular, and orthopaedic surgeries throughout the United States and Canada. The Company's BioGlue(R) surgical adhesive, CE marked in the European Union for use in vascular and pulmonary sealing and repair, is distributed throughout Europe. The Company also manufactures CryoLife-O'Brien(R) and CryoLife-Ross(TM) stentless porcine heart valves which are distributed within the European Community.

Statements made in this press release which look forward in time involve risks and uncertainties and are "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such risks and uncertainties include the possibility that the FDA will not approve human clinical trials of SynerGraft technology, the risk that SynerGraft heart valve technology will not perform in humans as it has in animals or that unforeseen complications may arise subsequent to the use of SynerGraft heart valves such as those relating to calcification and functionality, the possibility that SynerGraft heart valve technology will not be successfully developed, or if successfully developed, that surgeons may choose not to utilize SynerGraft heart valve technology, changes in economic cycles, competition from other companies, changes in laws and governmental regulations applicable to the Company and other risk factors detailed in the Company's Securities and Exchange Commission filings, including the Company's Prospectus dated March 30, 1998, contained in its Registration Statement on Form S-3 (No. 333-46545).

Editor's Note:

CryoLife Customer Service may be accessed by telephone: 1-800-438-8285 (U.S. and Canada) 1-770-419-3355 (International) 1-770-590-3753 (International fax) E-mail: customerservice@cryolife.com

For additional information about the Company, visit CryoLife's web site: <http://www.cryolife.com>

--30--md/na*

CONTACT: CryoLife Inc., Atlanta
Roy Vogeltanz, 800/438-8285

KEYWORD: GEORGIA
INDUSTRY KEYWORD: MEDICINE BIOTECHNOLOGY

